AnaptysBio’s (NASDAQ:ANAB) lock-up period is set to expire on Tuesday, July 25th. AnaptysBio had issued 5,000,000 shares in its initial public offering on January 26th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. After the end of the company’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Several research analysts have issued reports on ANAB shares. JMP Securities reissued an “outperform” rating and set a $45.00 price objective on shares of AnaptysBio in a research report on Friday, March 31st. Credit Suisse Group reissued an “outperform” rating and set a $34.00 price objective on shares of AnaptysBio in a research report on Tuesday, April 18th. Wedbush lowered their price objective on shares of AnaptysBio from $33.00 to $28.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 29th. Zacks Investment Research raised shares of AnaptysBio from a “sell” rating to a “hold” rating in a research report on Monday, May 29th. Finally, Stifel Nicolaus raised their price objective on shares of AnaptysBio from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, May 2nd. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $35.60.

ILLEGAL ACTIVITY WARNING: “AnaptysBio, Inc.’s (NASDAQ:ANAB) Lock-Up Period Set To End on July 25th” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/07/18/anaptysbio-inc-s-nasdaqanab-lock-up-period-set-to-end-on-july-25th.html.

Shares of AnaptysBio (NASDAQ ANAB) opened at 27.83 on Tuesday. The firm’s market cap is $564.09 million. The stock has a 50 day moving average of $24.76 and a 200 day moving average of $24.38. AnaptysBio has a 1-year low of $15.17 and a 1-year high of $29.96.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Thursday, May 11th. The biotechnology company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.57. Equities research analysts anticipate that AnaptysBio will post ($2.48) earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC purchased a new position in AnaptysBio during the first quarter valued at approximately $24,474,000. Bank of America Corp DE purchased a new position in AnaptysBio during the first quarter valued at approximately $123,000. Geode Capital Management LLC purchased a new position in AnaptysBio during the first quarter valued at approximately $1,522,000. Marshall Wace North America L.P. purchased a new position in AnaptysBio during the first quarter valued at approximately $6,924,000. Finally, MARSHALL WACE ASIA Ltd purchased a new position in AnaptysBio during the first quarter valued at approximately $6,924,000. Institutional investors and hedge funds own 72.59% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.